Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 2/20 | 0.84 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616547 | 0.91 | CD4 (1.00) | CD4SORT1TSHRALDH1A1NPSR1 | |
| SCHEMBL13925215 | 0.86 | CD4 (0.89) | CD4SORT1TSHRALDH1A1NPSR1 | |
| SCHEMBL4109293 | 0.86 | CD4 (0.89) | CD4SORT1TSHRKDM4EALDH1A1 | |
| SCHEMBL4103052 | 0.85 | CD4 (0.88) | CD4SORT1TSHRALDH1A1NPSR1 | |
| SCHEMBL13925191 | 0.85 | CD4 (0.70) | CD4SORT1TSHRCYP2D6CYP3A4 | |
| SCHEMBL21361470 | 0.84 | CD4 (0.86) | CD4SORT1TSHRALDH1A1NPSR1 | |
| SCHEMBL4274368 | 0.82 | CD4 (0.81) | CD4SORT1TSHRKDM4EALDH1A1 | |
| SCHEMBL13925203 | 0.82 | CD4 (0.68) | CD4SORT1TSHRKDM4EALDH1A1 | |
| SCHEMBL8679320 | 0.82 | CD4 (0.59) | CD4SORT1TSHRCYP2D6CYP3A4 | |
| SCHEMBL4114397 | 0.81 | CD4 (0.80) | CD4SORT1TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019423-A1 | Anti-viral triaza compounds | BELL THOMAS W (US) | 2002-02-14 | — | — | US | claimed |
| US-6342492-B1 | VIRICIDES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-01-29 | — | — | US | claimed |
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2009-02-19 | — | — | US | disclosed |
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2009-02-19 | — | — | US | disclosed |
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2009-02-19 | — | — | US | disclosed |
| US-20040220164-A1 | Triaza compound immunoregulatory agents | BELL THOMAS (US) | 2004-11-04 | — | — | US | disclosed |
| WO-2002080856-A2 | TRIAZA COMPOUND IMMUNOREGULATORY AGENTS | UNIVERSITY AND COMMUNITY COLLEGE SYSTEM OF NEVADA ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020019423-A1 | Anti-viral triaza compounds | BELL THOMAS W (US) | 2002-02-14 | — | — | US | disclosed |
| US-6342492-B1 | VIRICIDES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-01-29 | — | — | US | disclosed |
| EP-0809504-A4 | ANTI-VIRAL TRIAZA COMPOUNDS | UNIV NEW YORK STATE RES FOUND (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0809504-A1 | ANTI-VIRAL TRIAZA COMPOUNDS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025167-A1 | ANTI-VIRAL TRIAZA COMPOUNDS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019423-A1 | Anti-viral triaza compounds | ZC3HAV1, MAVS, BAZ1A | CD4 10/4885SORT1 4881/4885TSHR 2057/4885 |
| US-20040220164-A1 | Triaza compound immunoregulatory agents | CD4, NFATC1, IKZF3 | CD4 1/4885SORT1 4792/4885TSHR 463/4885 |
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | CD4, NFATC1, IKZF3 | CD4 1/4885SORT1 4792/4885TSHR 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.